MX2023014406A - Sistemas de edición de genes que comprenden un arn guía dirigido a hidroxiácido oxidasa 1 (hao1) y usos de estos. - Google Patents

Sistemas de edición de genes que comprenden un arn guía dirigido a hidroxiácido oxidasa 1 (hao1) y usos de estos.

Info

Publication number
MX2023014406A
MX2023014406A MX2023014406A MX2023014406A MX2023014406A MX 2023014406 A MX2023014406 A MX 2023014406A MX 2023014406 A MX2023014406 A MX 2023014406A MX 2023014406 A MX2023014406 A MX 2023014406A MX 2023014406 A MX2023014406 A MX 2023014406A
Authority
MX
Mexico
Prior art keywords
hao1
gene editing
editing systems
rna guide
gene
Prior art date
Application number
MX2023014406A
Other languages
English (en)
Spanish (es)
Inventor
Quinton Norman Wessells
Tia Marie Ditommaso
Jeffrey Raymond Haswell
Noah Michael Jakimo
Sejuti Sengupta
Original Assignee
Arbor Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbor Biotechnologies Inc filed Critical Arbor Biotechnologies Inc
Publication of MX2023014406A publication Critical patent/MX2023014406A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
    • C12Y101/03015—(S)-2-Hydroxy-acid oxidase (1.1.3.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2023014406A 2021-06-04 2022-06-03 Sistemas de edición de genes que comprenden un arn guía dirigido a hidroxiácido oxidasa 1 (hao1) y usos de estos. MX2023014406A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163197073P 2021-06-04 2021-06-04
US202163225046P 2021-07-23 2021-07-23
US202163292889P 2021-12-22 2021-12-22
US202263300727P 2022-01-19 2022-01-19
PCT/US2022/032144 WO2022256642A2 (en) 2021-06-04 2022-06-03 Gene editing systems comprising an rna guide targeting hydroxyacid oxidase 1 (hao1) and uses thereof

Publications (1)

Publication Number Publication Date
MX2023014406A true MX2023014406A (es) 2024-02-12

Family

ID=82694238

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014406A MX2023014406A (es) 2021-06-04 2022-06-03 Sistemas de edición de genes que comprenden un arn guía dirigido a hidroxiácido oxidasa 1 (hao1) y usos de estos.

Country Status (12)

Country Link
US (3) US20230032141A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347833A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024520691A (cg-RX-API-DMAC7.html)
KR (1) KR20240034746A (cg-RX-API-DMAC7.html)
AU (1) AU2022283922A1 (cg-RX-API-DMAC7.html)
CA (1) CA3222159A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023018656A2 (cg-RX-API-DMAC7.html)
IL (1) IL308803A (cg-RX-API-DMAC7.html)
MX (1) MX2023014406A (cg-RX-API-DMAC7.html)
PH (1) PH12023553297A1 (cg-RX-API-DMAC7.html)
TW (1) TW202317763A (cg-RX-API-DMAC7.html)
WO (1) WO2022256642A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119095956B (zh) * 2023-05-11 2026-01-23 尧唐(上海)生物科技有限公司 一种Cas蛋白、其相应的基因编辑系统及应用
WO2025147604A1 (en) 2024-01-05 2025-07-10 Arbor Biotechnologies, Inc. Methods for treating primary hyperoxaluria via genetic editing of hydroxyacid oxidase 1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3581654T1 (sl) * 2013-12-27 2021-08-31 Dicerna Pharmaceuticals, Inc. Postopki in sestavki za specifično inhibicijo glikolat-oksidaze (HA01) z dvoverižno RNA
PL3765615T3 (pl) * 2018-03-14 2023-11-13 Arbor Biotechnologies, Inc. Nowe enzymy i układy crispr ukierunkowane na dna
MX2021001070A (es) * 2018-07-31 2021-05-27 Intellia Therapeutics Inc Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1).
CN115698278B (zh) * 2020-03-31 2025-10-17 阿伯生物技术公司 包含Cas12i2变体多肽的组合物及其用途
US20230235305A1 (en) * 2020-06-16 2023-07-27 Arbor Biotechnologies, Inc. Cells modified by a cas12i polypeptide
CN113308451B (zh) * 2020-12-07 2023-07-25 中国科学院动物研究所 工程化的Cas效应蛋白及其使用方法

Also Published As

Publication number Publication date
WO2022256642A3 (en) 2023-01-12
US20230212541A1 (en) 2023-07-06
CO2023018656A2 (es) 2024-01-25
WO2022256642A2 (en) 2022-12-08
TW202317763A (zh) 2023-05-01
CA3222159A1 (en) 2022-12-08
PH12023553297A1 (en) 2024-03-18
US11821012B2 (en) 2023-11-21
AU2022283922A1 (en) 2023-12-07
JP2024520691A (ja) 2024-05-24
US20230032141A1 (en) 2023-02-02
EP4347833A2 (en) 2024-04-10
AU2022283922A9 (en) 2023-12-14
IL308803A (en) 2024-01-01
US20240254494A1 (en) 2024-08-01
KR20240034746A (ko) 2024-03-14

Similar Documents

Publication Publication Date Title
MX2023006566A (es) Sistemas crispr tipo v clase 2 diseñados por ingeniería.
PH12022551594A1 (en) Method for treating usher syndrome and composition thereof
MX2024002988A (es) Composiciones y metodos moduladores de la serpina.
WO2021158921A3 (en) Adenine base editors and uses thereof
EP4170029A3 (en) Modifying the specifity of plant non-coding rna molecules for silencing gene expression
WO2020051360A8 (en) Base editing for treating hutchinson-gilford progeria syndrome
MX2024002927A (es) Metodos y composiciones para modular un genoma.
PH12023553297A1 (en) Gene editing systems comprising an rna guide targeting hydroxyacid oxidase 1 (hao1) and uses thereof
AU2021216418A8 (en) Compositions and methods for targeting, editing or modifying human genes
WO2023015318A3 (en) Genome editing compositions and methods for treatment of cystic fibrosis
WO2023288304A8 (en) Context-specific adenine base editors and uses thereof
WO2022051020A3 (en) Systems, methods, and compositions for rna-guided rna-targeting crispr effectors
WO2023004439A3 (en) Genome editing compositions and methods for treatment of chronic granulomatous disease
SG11201907899TA (en) Method for replicating or amplifying circular dna
MX2023014774A (es) Nuevos sistemas de endonucleasas programables de arn tipo v.
WO2023070110A3 (en) Genome editing compositions and methods for treatment of retinitis pigmentosa
WO2023288332A3 (en) Genome editing compositions and methods for treatment of wilson's disease
WO2022256714A3 (en) Genome editing compositions and methods for treatment of wilson's disease
MX2022001080A (es) Metodos y composiciones para reducir la inmunogenicidad mediante inhibidores de celulas b no agotadores.
WO2021231263A3 (en) Nucleic acid amplification methods
MX2025000138A (es) Composiciones y metodos para edicion epigenetica
CN112867795A (zh) 用于执行羟基酸氧化酶1(hao1)基因编辑以治疗1型原发性高草酸尿症(ph1)的组合物和方法
WO2022034374A3 (en) Improved gene editing
MX2025004485A (es) Sistemas de edicion de genes que comprenden transcriptasas inversas
MX2025010781A (es) Sistemas y métodos de modulación de pah